The nationally and internationally recognized experts in the endocrine cancer research program at the OSUCCC – James often present their findings and accomplishments to medical experts from around the world through presentations, publications, and numerous national and international meetings and conferences they attend throughout each year.
This includes giving more than 100 scientific presentations annually, as well as earning laudable coverage in medical journal publications.
A snapshot of recent publications/presentations include:
1. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine.
2. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. J Clin Oncol. 2017 Aug 17. [Epub ahead of print] PubMed PMID: 28817373.
3. Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients With RET-Altered Thyroid Cancers: An Update From ASCO 2018. Wirth L, Cabanillas M, Sherman E, Solomon B, LeBoulleux S, Robinson B, Taylor MH, Bauer T, Patel J, Reckamp K, Lorch J, Tan D, Boni V, Smith S, Tuch B, Ebata K, Zhu E, Nguyen M, Huang X, Cruickshank S, Rothenberg SM, Oxnard G, Besse B, Schlumberger M, Drilon A, Subbiah V, Shah MH. Oral presentation at the 88th Annual Meeting of the ATA in Washington, DC, Oct 2018.
4. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase II Trial. Carneiro BA*, Konda B*, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae TK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. J Clin Endocrinol Metab. 2019 July 5. PMID: 31276163 (*Equal Contribution)
5. The Emerging Role of Targeted Therapies for Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cloyd JM, Konda B, Shah MH, Pawlik TM. Expert Rev Clin Pharmacol. 2018 Dec 24. PubMed PMID: 30582383